VAB‐6 combination chemotherapy in resected stage II‐B testis cancer Academic Article Article uri icon


MeSH Major

  • Cystadenocarcinoma
  • Prostatic Neoplasms


  • Twenty-four patients with resected Stage II-B nonseminomatous germ cell tumors of the testis received adjuvant chemotherapy with the modified VAB-6 regimen for one year. Eighteen patients had nodal category N2B and six nodal category N3 (extranodal extension of tumor). Adjuvant VAB-6 started with two four day inductions at approximately four week intervals. Induction was cyclophosphamide 600 mg/m2 IV, vinblastine 4 mg/m2 IV, dactinomycin 1 mg/m2 IV, bleomycin 30 mg IV on day 1, then bleomycin 20 mg/m2/day by continuous 24 hour infusion for three days, and cis-platinum 120 mg/m2 IV on day 4. Maintenance was vinblastine 6 mg/m2 IV and dactinomycin 1 mg/m2 IV every three weeks. Six patients received a third induction but without bleomycin. All 24 patients remain free of disease with a median follow up of 24 months. Myelosuppression was the major toxicity. Four patients received antibiotics for fever during myelosuppression. In one patient, serum creatinine temporarily rose over 2 mg/dl after cis-platinum. VAB-6 is effective in the prevention of recurrences in resected Stage II-B nonseminomatous germ cell tumors. However, the optimal regimen remains to be defined.

publication date

  • January 1983



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19830101)51:1<5::AID-CNCR2820510103>3.0.CO;2-J

PubMed ID

  • 6185195

Additional Document Info

start page

  • 5

end page

  • 8


  • 51


  • 1